CHICAGO - Tempus AI, Inc. (NASDAQ:TEM) announced Thursday the publication of a multi-site validation study for its FDA-cleared software that predicts one-year risk of atrial fibrillation or flutter. The study was published in Heart Rhythm, according to a press release statement. The company, valued at $8.88 billion, has seen its stock decline 30% over the past year despite reporting revenue growth of 70% in the last twelve months.
The research evaluated the Tempus ECG-AF software across three geographically distinct clinical sites. The software received FDA clearance in 2024 for predicting atrial fibrillation or flutter risk.
The study examined 4,017 patients aged 65 and older with no prior atrial fibrillation and no history of pacemaker or defibrillator use. ECG data were aggregated and patient charts were manually reviewed to identify eligible participants. Study endpoints included a new atrial fibrillation diagnosis within one year or one year of atrial fibrillation-free follow-up.
The ECG-AI-derived risk score surpassed pre-specified performance thresholds, and the resulting data supported the FDA clearance of the technology. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though the company maintains a "GOOD" financial health score. Investors can explore whether TEM ranks among the Most Overvalued stocks for deeper valuation insights.
"This study marks an important step toward shifting cardiac care from late-stage intervention to early risk detection," said Brandon Fornwalt, SVP of Cardiology at Tempus and a coauthor of the study. "The ability of our AI model to consistently predict atrial fibrillation across varied clinical environments highlights its potential as a dependable decision-support tool."
Tempus ECG-AF is intended to analyze recordings of 12-lead ECG devices and detect signs associated with a patient experiencing atrial fibrillation or atrial flutter within the next 12 months. The software is designed for use on resting 12-lead ECG recordings collected at healthcare facilities from patients meeting specific criteria.
The company stated that Tempus ECG-AF was the first FDA-cleared ECG-AI device in its portfolio of cardiovascular diagnostic devices. For comprehensive analysis of Tempus AI’s financial outlook and growth trajectory, InvestingPro offers a detailed Pro Research Report covering TEM alongside 1,400+ other US equities.
In other recent news, Tempus AI announced that the U.S. Food and Drug Administration approved its xT CDx next-generation sequencing platform for tumor-only genomic testing. This approval allows the test to function without needing a matched normal sample, marking a significant milestone for the company. Additionally, Tempus AI unveiled results from its multimodal foundation models at the 2026 American Society of Clinical Oncology Annual Meeting, showcasing its advanced transformer-based model trained on extensive datasets. In another development, Tempus AI launched a digital pathology IMS Open-Source Consortium alongside Yale New Haven Hospital and Memorial Sloan Kettering Cancer Center, aiming to develop an open-source digital pathology platform.
Canaccord Genuity reiterated a Buy rating for Tempus AI, emphasizing growth potential and setting a price target of $80. The firm’s confidence follows the company’s investor day, where Tempus presented growth drivers and financial expectations for its Diagnostics and Data and Applications segments. Meanwhile, Wolfe Research initiated coverage with a Peerperform rating, assigning a fair value range of $40 to $65 per share. Wolfe’s valuation is based on a combination of discounted cash flow models and sum-of-the-parts analysis. These recent developments highlight Tempus AI’s ongoing innovations and strategic positioning in the healthcare sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Most traders can read a chart. The hard part is the moment: entry window open, pattern forming, and you're still waiting for more confirmation. That's the conviction gap — and our chart analysis closes it. Unlike other AIs that just read data, our Vision AI literally "sees" your charts and hands you a complete trading plan: entry, stop-loss, and profit target in under 60 seconds. Know exactly what to do next, every time.